Operations • Transformation • Life Sciences

Rich Motruk

SVP, Client Operations & Transformation · Registrar Corp

Operations executive who scales life sciences organizations without sacrificing quality, from FDA remediation and production turnarounds to growing a professional services firm tenfold. Today I’m putting AI to work inside regulatory delivery at Registrar Corp.

10xHeadcount growth at Kymanox (30 to ~300)
$70M+Revenue scaled from $7M
25%+EBITDA margins sustained through hypergrowth
96%Reduced peak-season effort through AI automation
Career Accomplishments

Results that moved the business

Registrar Corp

Putting AI to Work in Regulatory Delivery

When I joined Registrar Corp in 2026, much of our regulatory delivery work was still manual. I set a simple rule for AI adoption: apply it where work is high-volume and repetitive, and keep a qualified expert accountable for every output that reaches a client.

In Drug Services, the team built an in-house automation tool in one week, with no new vendor or license, that reduced a peak-season workload from roughly a month of effort to about a day and freed an estimated 200 staff hours per cycle while eliminating manual keying errors.

In Food Safety Services, AI now supports the majority of steps in our core compliance program workflow. In Label Services, an AI-assisted drafting pilot cut preparation time by 50–63%, with broader rollout under way. Across these projects, time saved is reinvested in expert review and client work, not in cutting corners on quality.

Lifting Productivity Across Delivery Teams

I brought operating fundamentals to consultative regulatory work: clear workflows, productivity and time-to-value metrics, and capacity planning tied to demand.

In Food Safety Services, output per FTE rose 62% within the year and total monthly output grew 45%. When demand outpaced delivery capacity, I restructured the work so new clients see results soon after onboarding while a dedicated team works down existing commitments in priority order.

In Label Services, productivity reached 30% above the prior-year average, with more than 90% of work accepted on the first pass.

Reducing Backlog and Time to Value

In Drug Services, deliberate backlog management reduced long-aged open work by 85% in twelve months and cut typical turnaround time by more than half, even as volume surged.

Lowering the Cost to Serve

Within eight months, I delivered projected net annualized savings of 13.5% across Client Operations by right-sizing teams as productivity improved, streamlining offshore operations, and building a lower-cost delivery mix, all while protecting delivery quality and the Registrar brand.

Kymanox

Scaling Operations for Hypergrowth

As Chief Operating Officer at Kymanox, a professional services organization specializing in life sciences, I spearheaded initiatives to enable rapid scaling during a hypergrowth period from 2019 to 2022, growing the company from 30 to approximately 300 employees, and $7MM to north of $70MM in revenue. Kymanox generates revenue primarily through time-and-materials contracts, making compensation the largest expense and underutilized capacity the greatest threat to profitability. To address this, I established robust business processes to support growth while ensuring capacity aligned with demand. A key component was implementing a pipeline recruiting strategy and forging partnerships with recruiting and staffing firms to onboard qualified talent rapidly, avoiding premature hiring. These efforts maintained EBITDA margins north of 25%, demonstrating strong financial health and attracting private equity investment in 2021. By aligning operational capacity with market needs, we ensured sustainable growth while maximizing profitability and client satisfaction.

Optimization of Innovation Resource Planning

At Kymanox, our highly matrixed organization delivers solutions through team members who often juggle three to five client projects weekly, with fractional time allocations that vary based on project demands. As the company scaled, forecasting available capacity became increasingly challenging, hindering business development, budgeting, and hiring decisions. There was no available out-of-the-box software solution. I led the development and implementation of a customizable resource management tool that provided clear visibility into projected utilization by individual, skill set, and department. This tool enabled data-driven decisions, optimizing hiring strategies, supporting accurate budgeting, and ensuring resources were allocated efficiently to meet client needs. The result was enhanced client satisfaction, improved project delivery, and sustained profitability, reinforcing Kymanox's ability to operate effectively in a dynamic, project-driven environment.

Client Project Successes

Overhaul of CDMO Production and Quality Systems

I led a critical engagement for a contract development and manufacturing organization (CDMO) facing production and quality challenges with a client's biologic therapeutic. My team overhauled their root cause analysis and non-conformance processes, implementing best-in-class operations in preparation for a pre-approval inspection (PAI). I also developed and delivered training to enhance the client's staff capabilities in applying statistical hypothesis tools, enabling more accurate root cause identification, streamlined corrective actions, and reduced timelines for investigations and corrective and preventive actions (CAPAs). These improvements not only resolved the immediate quality issues but also positioned the CDMO as a leader in operational excellence, ensuring regulatory compliance and client confidence ahead of the PAI.

Pioneering FDA Compliance for Emergency Use Devices

In 2017, I led a groundbreaking effort to meet new FDA requirements for emergency use devices, such as epinephrine auto-injectors, which mandated demonstrating 99.999% reliability with 95% confidence (a significant increase from the prior 99.9% threshold) for a product already on the market. Leveraging my expertise in root cause investigations, production controls, and statistical analysis, I developed variable sampling plans, manufacturing controls, and statistical strategies that became the industry standard for new commercial approvals of emergency use devices. This expertise led to my selection by Pfizer's Meridian Medical Technologies to address a warning letter concerning EpiPen performance. My efforts identified and resolved the primary performance issue, avoiding substantial planned capital expenditures and preventing escalation of the warning letter. The issue was fully resolved based on my findings and recommendations, underscoring the impact of rigorous statistical methodologies and strategic problem-solving in high-stakes regulatory environments.

bioMérieux

Overhaul of Production Controls to Address FDA Warning Letter

As Manager of the Engineering Department at bioMérieux's Durham facility, my first assignment was to address critical deficiencies in production controls, which had been repeatedly flagged by the FDA through consecutive Form 483 observations and culminated in a warning letter issued during my first week. Drawing on my prior experience at OraSure, I led the deployment of an enterprise-level statistical process control software package to enable a robust continuous process verification plan. This initiative involved a comprehensive review and modification of in-process inspections and sampling strategies, each supported by rigorous statistical justifications. The implementation of these measures significantly reduced process variation, as evidenced by enhanced process monitoring and control charts. Ultimately, these efforts fully resolved the FDA's concerns, satisfying the requirements outlined in prior regulatory actions and averting a costly consent decree. By achieving compliance, we safeguarded the company from millions of dollars in potential fines and operational disruptions, reinforcing the value of proactive regulatory strategies and data-driven process improvements.

Resolution of Production Yield and Supply Chain Issues

Upon joining bioMérieux, I inherited a facility struggling to meet product demand due to poor production line yields, which threatened market share as customers turned to competitors. I led a cross-functional team to investigate and address the root causes of downtime impacting throughput. We identified two primary issues: frequent automation communication faults and limitations on media filling times. To tackle the automation faults, I spearheaded an operational expenditure investment to hire dedicated automation engineers, secured capital funding to upgrade programmable logic controllers (PLCs), and enhanced remote troubleshooting capabilities to reduce time-consuming gowning procedures for on-site repairs. For the media filling issue, I led a revalidation effort that extended allowable filling times by eight hours, based on updated validation studies demonstrating process reliability. Additionally, I championed the introduction of a weekend shift to establish a true 24/7 operation. These combined efforts increased production line throughput by 35%, fully resolving supply chain shortages and enabling bioMérieux to recapture lost market share. This experience highlighted the impact of targeted capital investments, process revalidation, and operational restructuring in restoring production capacity and competitive positioning.

OraSure Technologies

Automation of Manual Assembly Process

At OraSure Technologies, a pioneer in developing the first lateral flow, oral fluid-based, point-of-care assay for HIV detection, I led a transformative initiative to transition the manual assembly process to a fully automated production line. The objective was to enhance yield, improve quality, reduce variation, and lower the cost of goods sold (COGS). Given the unique design and use requirements of the device, this required commissioning custom automation equipment tailored to the assay's specifications. I also developed a revised sampling plan, leveraging advanced statistical methods to justify the approach, ensuring compliance with regulatory standards. The results were significant: production throughput increased by over 100%, and defect rates decreased by 10%. This project not only optimized operational efficiency but also reinforced the importance of integrating innovative automation with rigorous statistical validation to achieve sustainable improvements in manufacturing.

Overhaul of Production Controls to Address FDA 483s

While at OraSure Technologies, I was tasked with overhauling the organization's production controls in response to a series of FDA Form 483 observations identifying deficiencies. I conducted a comprehensive review of all sampling plans, testing protocols, and in-process controls, modifying them as needed and implementing additional controls where deficiencies were identified. To proactively ensure compliance and process reliability, I introduced a novel continuous process verification system based on statistical process control, one of the first in the industry. This system provided real-time assessment of the manufacturing process against its validated state, triggering investigations and corrective actions when deviations occurred. The revamped controls and verification system fully resolved the FDA's concerns, as confirmed during their subsequent inspection. This experience underscored the value of strategic regulatory compliance and innovative process monitoring in maintaining high-quality standards.

Resolution of Assay Quality Issue

Upon joining OraSure Technologies, my first assignment was to address a critical quality issue affecting the functional performance of the HIV assay, which had seen a rise in false positives, leading to 30% of all product being discarded, a stark decline from its performance at commercial launch. Leveraging my Six Sigma training, I led a root cause investigation, assembling a cross-functional team of top scientists, engineers, and subject matter experts. By collaborating with IT specialists to integrate disparate data sets, I oversaw the statistical and data analyses that traced the issue to a raw material that had drifted within its approved tolerances. The team collaborated with the vendor to adjust their manufacturing process, establishing a new tolerance window that fully resolved the issue. The insights gained from this data integration effort prompted the development of a database tool with a custom user interface by a third-party provider, to allow non-database experts to use it efficiently, which became the foundation for all future root cause analyses at OraSure. This project highlighted the power of data-driven problem-solving and cross-disciplinary collaboration in restoring product quality and operational reliability.

Teva Pharmaceuticals

Solid Dose Packaging Turnaround

Early in my career, at the age of 25, I was entrusted with the role of Senior Supervisor for the Solid Dose Packaging department at Teva Pharmaceuticals. This 3-shift, 24-hour, five-day-a-week operation was the facility's primary bottleneck, constrained by limited space and capital equipment. My mandate was to enhance operational efficiency without additional investment. Through detailed analysis, I identified equipment downtime as the primary limitation, driven by three key factors: major line changeovers, equipment setup, and restricted operating hours. Major changeovers, required to reconfigure lines for different products while ensuring no cross-contamination, averaged eight hours and occurred multiple times weekly across five packaging lines. By implementing a Lean Manufacturing Single Minute Exchange of Die (SMED) initiative, I led a cross-functional team to streamline and standardize the process, reducing changeover time to under three hours. Additionally, equipment setups, which depended on maintenance personnel often unavailable during changeovers, were optimized by developing standardized procedures and training dedicated packaging staff to perform these adjustments. This initiative included incentivizing staff with updated job roles, increased compensation, and performance-based bonuses. Finally, I spearheaded the transition to a 24/7 operation by introducing a weekend shift. Collectively, the changeover and setup improvements generated an additional $500,000 in weekly revenue, while the expanded operating schedule contributed another $800,000 weekly, all achieved without capital expenditure. This experience underscored the value of strategic leadership and collaborative problem-solving in driving significant operational improvements.

Fluid Bed Changeover Reduction

Following the success of my initiatives in the Solid Dose Packaging department at Teva Pharmaceuticals, I was promoted to a Process Engineering role, later formalized as a Continuous Process Improvement Engineer. My new mission was to identify and address inefficiencies across the plant's diverse pharmaceutical manufacturing operations. Through a comprehensive evaluation of material flows and cycle times, I pinpointed the Fluid Bed operation, a critical process for producing numerous solid dose therapeutics, as one of the most complex and constrained due to its lengthy changeover times. These changeovers, essential for transitioning between products, averaged six hours, significantly limiting the production suite's throughput. I led a collaborative project with the fluid bed operators to analyze and streamline the changeover process, implementing standardized procedures and leveraging operator insights to enhance efficiency. As a result, we reduced changeover times by 50%, from six hours to three, enabling the processing of two additional batches per week. This improvement markedly increased the suite's capacity and output without requiring additional capital investment, reinforcing the impact of data-driven analysis and team collaboration in optimizing complex manufacturing processes.

Education

Education & certification

PSU

The Pennsylvania State University

B.S. Biochemistry & Molecular Biology

1998 – 2001

ASQ

American Society for Quality

Certified Six Sigma Black Belt

2005 – 2006

Experience

Career history

Registrar Corp

February 2026 – Present

registrarcorp.com
SVP, Client Operations & TransformationFebruary 2026 – Present

I lead client operations and transformation at Registrar Corp, a regulatory compliance firm that helps food, beverage, cosmetic, medical device, and drug companies meet U.S. FDA requirements. My organization spans onshore and offshore teams and owns the client experience from the signed deal forward: onboarding, implementation, tech-enabled and consultative service delivery, and renewals.

I set four priorities for the organization: protect the quality and reputation of the Registrar brand, lower our cost structure, bring operating fundamentals to consultative services, and embed AI across delivery.

Early results include projected net annualized savings of 13.5% achieved within eight months, double-digit productivity gains across Food Safety and Label Services, a significant reduction in aged backlog in Drug Services, and AI-enabled projects delivered across Drug, Food Safety, and Label Services. Every AI-assisted output is reviewed and approved by a qualified expert before it reaches a client.

Kymanox

August 2016 – January 2026

kymanox.com
Chief Operating OfficerSeptember 2018 – January 2026

As Chief Operating Officer at Kymanox from 2018, I had the privilege of steering a dynamic professional services firm through a period of extraordinary growth, transforming it from a nimble team of 30 with $7 million in revenue to a powerhouse of roughly 300 professionals generating north of $70 million. My journey at Kymanox is a testament to strategic foresight, adaptive leadership, and a relentless focus on balancing growth with quality, a challenge I met head-on in the fast-paced life sciences industry.

When I joined Kymanox, we were a small but mighty player, known for delivering high-quality solutions in biotechnology, pharmaceuticals, and medical devices. By 2019, we identified two hyper-growth areas that would define our trajectory: helping clients secure regulatory approval and commercialize combination products (therapeutics paired with delivery systems like auto-injectors, nasal sprays, and pre-filled syringes) and FDA remediation (addressing 483s, Warning Letters, and Consent Decrees). These opportunities were exciting but came with a critical challenge: scaling our organization to meet surging demand without compromising quality or profitability.

In a professional services firm, scaling is a delicate balance. Grow too slowly, and you miss opportunities, risk turning down work, or deliver subpar results, damaging your reputation. Grow too fast, and expenses outpace revenue, eroding profitability, especially when underutilized capacity is the single biggest cost. As COO, my mission was to align supply with demand, building infrastructure and client-facing capacity to capitalize on these growth areas while maintaining Kymanox's reputation for excellence.

For the combination products segment, which could be delivered remotely, I developed a strategy to create a flexible, scalable talent pipeline. I built a network of pre-vetted, highly experienced engineers, scientists, and quality professionals, negotiating compensation packages in advance to enable rapid onboarding as projects were secured. This approach allowed us to quickly assemble tailored teams, ensuring we met client needs for regulatory submissions and commercialization without overstaffing. The result? We supported clients in launching innovative delivery systems, like on-body injectors, while maintaining project timelines and quality standards.

FDA remediation, however, required a different approach. These projects often demanded on-site presence for implementing mitigations and corrective actions, particularly for high-stakes Consent Decree responses. Building a network for every geographic location was impractical, so I forged strategic partnerships with recruiting and staffing firms with extensive databases. We complemented this by making key hires and, when necessary, relocating seasoned Kymanox staff to lead large-scale, on-site projects. This ensured that new resources integrated seamlessly, delivering the quality and branding Kymanox is known for, even under intense regulatory scrutiny.

These strategies paid off in spades. From 2018 to 2021, Kymanox grew from 60 to 180 people and revenue soared from $7 million to $33 million, with an EBITDA near 30%, a near-unheard-of margin for a professional services firm. Our success attracted private equity investment in 2021, fueling further expansion, both organic and inorganic, to approximately 300 employees and north of $70 million in revenue. This growth wasn't just about numbers; it was about building a sustainable, high-performing organization that empowered our team and delivered transformative solutions for our clients.

Sr. Director of Technical ServicesSeptember 2016 – August 2018

As Senior Director of Technical Operations, I led a team of four direct reports managing our Chemistry & Manufacturing Controls, Commissioning/Qualification/Validations, Project Management Office, and Technical Services teams, with the organization consisting of an additional 40 indirect reports in a highly client-facing role.

My organization drove a comprehensive operations overhaul for an aseptic filling company, enhancing manufacturing and quality assurance processes to improve compliance for critical hospital supplies. I provided technical and regulatory guidance to a biotech client, preparing them for a successful FDA premarket approval inspection by managing non-conformance and CAPA investigations, and led the optimization of a client's production controls and surveillance programs to ensure compliance and drive quality improvements.

One of my proudest achievements was guiding our team to meet the FDA's groundbreaking 2016 performance standards for emergency-use devices, such as the EpiPen auto-injector. This was a pivotal moment that not only ensured continued market success for our clients but also positioned Kymanox as the go-to provider for companies navigating this high-stakes regulatory landscape.

In 2016, the FDA redefined expectations for emergency-use devices, critical for conditions like anaphylaxis, demanding an unprecedented failure rate of no more than 1 in 100,000 uses in the field, down from the previous 1 in 1,000 standard. This 100-fold increase in reliability posed complex challenges, requiring innovative approaches to design, engineering, manufacturing, and statistical sampling.

The stakes were sky-high: failure to comply could disrupt the availability of life-saving devices like the EpiPen. I took direct responsibility for partnering with Meridian Medical Technologies (then a Pfizer subsidiary) to keep the EpiPen on the market by addressing these rigorous standards. Leading a team of engineers, regulatory experts, and quality professionals, we developed robust strategies to enhance design reliability, optimize manufacturing processes, and implement rigorous statistical validation protocols, ensuring the EpiPen met the FDA's new expectations and remained available for patients who depend on it.

This success wasn't just a win for one client; it set a new standard for the industry. Under my leadership, Kymanox became the industry leader in helping clients secure FDA approval for new emergency-use devices, from auto-injectors to nasal sprays.

bioMérieux

May 2013 – August 2016

biomerieux.com
Director of ManufacturingJanuary 2015 – July 2016

As Director of Manufacturing at bioMérieux's Durham, North Carolina site, I took the helm of a high-stakes 24/7 operation, leading a team of nearly 200 professionals with an operating budget exceeding $23 million. Reporting directly to the Site Director, I oversaw three production lines, a packaging line, formulation, and cleaning operations, while serving as a key member of the Corrective and Preventive Action (CAPA) and Material Review Board (MRB) committees.

My leadership team consisted of seven direct reports: four Manufacturing Managers, a Packaging Manager, a Senior Manager of Maintenance, and a Senior Manager of Facilities. Within weeks of stepping into the role, I identified an opportunity to enhance production efficiency by establishing robust production controls during machine set-up that tightened the filling targets that had to be achieved before transitioning into production mode. This initiative led to a 10% increase in throughput.

The optimized set-up targets slightly extended the transition from set-up to production mode but delivered longer, more reliable runs with higher yields and fewer quality issues. This approach reduced deviations and CAPAs, streamlining operations and reinforcing our commitment to quality under FDA regulations (21 CFR Part 820).

As a member of the site leadership team, I implemented a cross-training program to enhance labor flexibility, enabling staff to shift seamlessly between production lines and packaging tasks, and standardized work processes for line supervisors and group leads. These changes built a more cohesive, adaptable team, ready to tackle the demands of a 24/7 operation. Serving on the CAPA and MRB boards, I brought a manufacturing lens to quality and compliance discussions, ensuring root causes were addressed swiftly and nonconforming materials were managed effectively.

Sr. Manager of Engineering, Maintenance & FacilitiesMay 2013 – December 2014

As Senior Manager of Engineering, Facilities & Maintenance, I led a team of 60 professionals at a high-profile life sciences manufacturing site, overseeing a $12 million operating budget and delivering transformative results under intense regulatory scrutiny, with 11 direct reports including Engineering & Industrialization Managers, a CAD Manager, a Sterilization Manager, and an Automation Senior Manager.

Appointed as the subject matter expert to address FDA observations that had escalated to a Warning Letter, I spearheaded a comprehensive overhaul of the site's production controls program. I restructured the engineering and maintenance teams into a multi-disciplinary, operations-focused group, boosting equipment reliability and availability and increasing site capacity by 30%. This transformation ensured compliance with 21 CFR Part 820 and restored regulatory confidence.

A key driver of this success was the strategic deployment of $5–15 million in annual capital funds, including advanced Statistical Process Control (SPC) software (InfinityQS) and the capital request to implement a Computerized Maintenance Management System (CMMS) and a Computerized Calibration Management System (CCMS), enabling predictive maintenance and reliability engineering principles.

Collaborating with Quality Assurance, I revamped Quality Control (QC) sampling protocols using risk-based approaches, saving $1–2 million annually while maintaining compliance. I also optimized bottle-filling processes, extending run times to increase capacity by at least 25% without additional capital expenditure.

OraSure Technologies

May 2008 – May 2013

orasure.com
Manager of Process ImprovementJanuary 2011 – May 2013

As the Senior Manager of Engineering at OraSure, I spearheaded a range of initiatives that significantly enhanced manufacturing processes, product quality, and operational efficiency. Leading a compact team of mechanical and chemical engineers, I oversaw the maintenance and optimization of diverse manufacturing processes and analytical test methods, and conducted in-depth investigations into complex non-conformances.

A key accomplishment was guiding the company through a transformative shift from manual to automated device and assay assembly. This involved commissioning custom automation equipment and navigating complex regulatory requirements to secure FDA and EMA approval for changes in lot release strategies. My team prepared comprehensive regulatory dossiers that demonstrated the improvements in sampling and release strategies, resulting in a 300% increase in throughput and a significant reduction in quality issues.

I also drove impactful quality and cost-saving initiatives, notably achieving substantial raw material cost reductions for cryogen products and OraQuick labeling without compromising quality.

Sr. Process Improvement EngineerJanuary 2010 – December 2010

As an investigator for customer complaints, I ensured thorough and effective resolutions, maintaining customer trust and product reliability. I supported R&D with statistical analyses and manufacturability insights, most notably reducing the rejection rate of an infectious disease diagnostic product from over 30% to under 0.5% by identifying and controlling critical quality parameters, guiding the lead scientist through the root cause investigation and subsequent process improvements.

Beyond process improvements, I collaborated with IT to develop a custom database for manufacturing and quality data analysis, delivered statistical training to the local ASQ chapter, generated Monte Carlo simulations to optimize kit sizes for the cryosurgery business, and conducted operational assessments of potential acquisitions.

Teva Pharmaceuticals

January 2002 – April 2008

teva.com
Process EngineerMarch 2007 – May 2008

I led a high-performing team of engineers, fostering a culture of continuous improvement and technical excellence. As an ASQ-certified Six Sigma Black Belt, I spearheaded a Six Sigma project focused on optimizing solid dose packaging operations. Applying lean tools such as SMED, process flow mapping, FMEAs, Pareto Analysis, and Capability Analysis, I reduced equipment changeover times by 60%, increasing monthly revenues by approximately $500,000.

I also led a Kaizen event to implement standardized work instructions and checklists across packaging lines, reducing onboarding time for new technicians by an estimated 25%. I mentored a Green Belt candidate through certification and developed and delivered Design of Experiments (DOE) training to operations managers and Green Belt candidates, with at least three subsequent trainee-led projects yielding measurable cost savings.

Sr. Operations Supervisor – Solid Dose PackagingJanuary 2005 – March 2007

I managed a diverse team of 51 employees, including operators, technicians, and supervisors, across three shifts and five packaging lines for solid dose products. I developed and implemented daily, weekly, and monthly packaging schedules that balanced production demands with equipment maintenance and staffing constraints, increasing overall equipment effectiveness (OEE) by an estimated 15%.

Regular team meetings reduced production delays by approximately 20%, and a performance tracking system for output, reject rates, and changeover times empowered team members and fostered a data-driven culture. I also created a coordination template between Packaging and Finished Dosage that reduced the impact of R&D activities on commercial output by 40%.

Bioequivalence & Pharmacokinetic Study ManagerMay 2003 – December 2004

I coordinated and managed 20 annual BE and PK studies critical to Teva's Abbreviated New Drug Application (ANDA) submissions, overseeing all aspects of study execution from protocol development to final reporting. All 20 studies were completed on schedule, with 100% submission acceptance by regulatory authorities.

I developed detailed study protocols defining dosing regimens, sampling schedules, and statistical endpoints (AUC and Cmax), ensuring studies were powered appropriately to demonstrate bioequivalence. This reduced the need for repeat studies, saving an estimated $1 million annually in clinical trial costs.

Quality Assurance Auditor & InvestigatorJanuary 2002 – April 2003

I reviewed batch records for solid, liquid, and parenteral products to ensure compliance with GMP, FDA, and EMA regulations, processing an estimated 50–60 batch records per month with a 98% on-time release rate.

I conducted thorough investigations into non-conformances such as out-of-specification results, equipment malfunctions, and operator errors, using root cause analysis tools like fishbone diagrams, 5-Why analysis, and fault tree analysis.

McNeil Consumer Healthcare

January 2001 – July 2001

jnj.com
Research Associate – Co-OpJanuary 2001 – July 2001

I suspended my education at Penn State for the Spring and Summer semesters of 2001 to gain industry experience in a pharmaceutical company, where I knew I wanted to work upon graduation. I worked as an associate analyst in a research and development laboratory, learning electron microscopy, HPLC test method development, and dissolution assays, among a host of other analytical techniques, in a commercial setting.

Insight

Beyond the résumé

Contact

Contact Rich

Always open to conversations with leaders who share a vision for advancing life sciences through operational excellence.

✉rmotruk@gmail.com